First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Average Target Price of $72.17

First Tracks Biotherapeutics (NASDAQ:TRAX) has been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $72.17.

TRAX has been the subject of several recent research reports. Leerink Partners lifted their price objective on First Tracks Biotherapeutics from $70.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, October 16th. Barclays boosted their price objective on First Tracks Biotherapeutics from $48.00 to $65.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Guggenheim upped their target price on shares of First Tracks Biotherapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Wall Street Zen raised shares of First Tracks Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $57.00 target price on shares of First Tracks Biotherapeutics in a report on Thursday, September 3rd.

First Tracks Biotherapeutics Price Performance

Shares of NASDAQ TRAX traded down $1.60 during mid-day trading on Friday, hitting $47.10. The company had a trading volume of 462,166 shares, compared to its average volume of 718,417. The company has a market capitalization of $1.98 billion and a PE ratio of -16.88. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $54.78. The business’s 50-day simple moving average is $39.90 and its 200 day simple moving average is $32.49.

First Tracks Biotherapeutics (NASDAQ:TRAX) last released its earnings results on Tuesday, November 3rd. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, analysts expect that First Tracks Biotherapeutics will post -4.24 EPS for the current year.

Insider Buying and Selling at First Tracks Biotherapeutics

In other news, Director J. Ware sold 39,265 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $44.78, for a total value of $1,758,286.70. Following the completion of the transaction, the director owned 15,660 shares in the company, valued at approximately $701,254.80. This represents a 71.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Institutional Investors Weigh In On First Tracks Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp purchased a new position in shares of First Tracks Biotherapeutics during the second quarter worth about $30,439,000. HighVista Strategies LLC acquired a new stake in shares of First Tracks Biotherapeutics during the third quarter worth about $2,473,000. Opaleye Management Inc. purchased a new stake in shares of First Tracks Biotherapeutics in the 2nd quarter valued at about $1,308,000. Wellington Management Group LLP purchased a new stake in shares of First Tracks Biotherapeutics in the 2nd quarter valued at about $1,156,000. Finally, Tidal Investments LLC acquired a new stake in shares of First Tracks Biotherapeutics in the 2nd quarter valued at about $622,000.

First Tracks Biotherapeutics Company Profile

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.